The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

A.N. Boyko

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

V.M. Alifirova

Siberian State Medical University

I.G. Lukashevich

Orden of the Red Banner of Labor City Clinical Hospital No. 1

Z.A. Goncharova

Rostov State Medical University

I.V. Greshnova

Regional Clinical Hospital

L.G. Zaslavsky

Pavlov First Saint Petersburg State Medical University

S.V. Kotov

Vladimirsky Moscow Regional Research Clinical Institute

N.A. Malkova

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

G.N. Mishin

Pyatigorsk City Clinical Hospital No. 2

E.V. Parshina

Semashko Nizhny Novgorod Regional Clinical Hospital

I.Ye. Poverennova

Seredavin Samara Regional Clinical Hospital

L.N. Prakhova

N. Bechtereva Institute of the Human Brain

S.A. Sivertseva

Medical and Sanitary unit «Neftyanik»

I.V. Smagina

Altai State Medical University

N.A. Totolyan

Academician I.P. Pavlov First Saint Petersburg State Medical University

Yu.V. Trinitatsky

Rostov Regional Clinical Hospital

T.N. Trushnikova

Wagner Perm State Medical University

F.A. Khabirov

City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education

J.Yu. Chefranova

Belgorod Regional Clinical Hospital of St. Joasaph

S.G. Shchur

Municipal Filatov Clinical Hospital No. 15

V.A. Dudin

Center for Cardiology and Neurology»

D.V. Pokhabov

Federal Siberian Scientific and Clinical Center

D.D. Bolsun

AO BIOCAD

A.V. Eremeeva

JSC BIOCAD

Yu.N. Linkova

AO BIOCAD

A.V. Zinkina-Orikhan

AO BIOCAD

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Authors:

A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, J.Yu. Chefranova, S.G. Shchur, V.A. Dudin, D.V. Pokhabov, D.D. Bolsun, A.V. Eremeeva, Yu.N. Linkova, A.V. Zinkina-Orikhan

More about the authors

Views: 1096

Downloaded: 10


To cite this article:

Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IYe, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YuV, Trushnikova TN, Khabirov FA, Chefranova JYu, Shchur SG, Dudin VA, Pokhabov DV, Bolsun DD, Eremeeva AV, Linkova YuN, Zinkina-Orikhan AV. Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7‑2):43‑52. (In Russ.)
https://doi.org/10.17116/jnevro202312307243

Recommended articles:
New neuroimaging methods in asse­ssing the acti­vity of neuroinflammation in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(7-2):8-14
Changes in venous circulation in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(7-2):22-28
Rela­tionship of patients with multiple scle­rosis to vaccination against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(7-2):29-33
A clinical case of multiple scle­rosis with an episode of schi­zophrenia-like syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(4):120-124
BDNF gene RS6265 poly­morphism in patients with multiple scle­rosis of Tomsk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(5):160-164

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.